Skinvisible Enters US License Agreement for New Prescription Product

Womens Choice Pharmaceuticals to Launch Product in Early 2011

Las Vegas, NV- December 14, 2010 - Further to its press release of April 13, 2010, Skinvisible, Inc. (SKVI:OTCBB) is pleased to announce it has entered into an exclusive licensing agreement after successfully completing the development of a prescription product for Women's Choice Pharmaceuticals LLC, a specialty pharmaceutical company based in Gilbert, Arizona. Skinvisible concluded the development phase for the hemorrhoid formulation using Skinvisible's technology Invisicare®, a patented polymer delivery system for topical dermatology and consumer goods products. The product has been formulated with the active ingredients hydrocortisone acetate and pramoxine hydrochloride.

Under the terms of the agreement, Skinvisible and Womens Choice Pharmaceuticals will now enter into the second phase of the agreement which grants the exclusive rights to commercialize the product within the United States. The agreement includes a license fee paid in milestones plus on-going royalties based on product sales. The product will be launched as a prescription product focused on the women's health market. This exclusive license expands Womens Choice's product line which will be launched at the beginning of the second quarter of 2011. "This is another important step for Skinvisible as we now have several ongoing agreements for prescription products and continued interest for additional products both in the US and internationally," said Mr. Terry Howlett, President and CEO. "This recent development illustrates the versatility of Skinvisible's Invisicare technology which provides patent-protected products not only in dermatology but other markets where topical products are sold."

At any one time over 1.3 million people in the United States suffer from hemorrhoids, with over 500,000 new cases being added each year. In 2006, the prescription market produced over $85 million in sales. Womens Choice forecasts this new product to generate $20 million annually by its third year.

Women's Choice Pharmaceuticals is an innovative specialty pharmaceutical company whose primary focus is to provide high quality prescription products to healthcare providers in the United States. Their nationwide sales force will deploy in the second quarter of 2011 and will target more than 30,000 OB/GYNS and selected other medical specialties. Their managed markets division will target PBM's, HMO, GPO, CMS and other managed care organizations ensuring their products are covered under drug benefit plans. (www.wcpharma.com )

Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing irritation. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. Skinvisible's value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. www.skinvisible.com and www.invisicare.com

Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10K for the quarter ending October 31, 2010).